Literature DB >> 26037791

Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.

A A Al Nofal1, O Altayar, K BenKhadra, O Q Qasim Agha, N Asi, M Nabhan, L J Prokop, P Tebben, M H Murad.   

Abstract

UNLABELLED: The aim of this systematic review and meta-analysis is to study the utility of the commonly used bone turnover markers in evaluating disease activity in patients with Paget's disease of bone before and after treatment with bisphosphonates. We found good correlation between the bone turnover marker concentrations and disease activity assessed by bone scintigraphy.
INTRODUCTION: Paget's disease of bone is a common skeletal disorder of the elderly. Bone turnover marker concentrations are used for diagnosis and follow-up. We aimed to compare the available bone turnover markers and determine their utility in assessing disease activity when compared to quantitative bone scintigraphy.
METHODS: We conducted a systematic review and meta-analysis searching MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. We evaluated total alkaline phosphatase (total ALP), bone-specific alkaline phosphatase (bone ALP), procollagen type 1 amino-terminal propeptide (P1NP), serum, and urine C-terminal telopeptide (uCTx and sCTx, respectively), and urine N-terminal telopeptide (uNTx). The main outcome of interest was the correlation of disease activity with concentrations of bone turnover markers in Paget's disease patients before and after treatment with bisphosphonates. Correlation coefficients were pooled across studies using the random effects model.
RESULTS: We included 17 observational studies and one trial reporting on 953 patients. Prior to treatment, all studied bone turnover markers had moderate to strong correlation with scintigraphic indices (correlation coefficients ranging from 0.58 to 0.80) with no statistically significant difference between the bone turnover markers overall (p = 0.08). P1NP, uNTx, and bone ALP tend to have higher correlation with scintigraphy. After starting treatment with bisphosphonate, there was moderate to strong correlation with disease activity with all markers except bone ALP (correlation coefficients ranging from 0.43 to 0.70).
CONCLUSION: The findings of this meta-analysis suggest the Paget's disease activity is best monitored by following P1NP levels. However, total ALP, bone ALP, and uNTx are good alternatives as markers of disease activity in untreated patients. Total ALP and uNTx can be useful in following patients with Paget's disease after treatment if P1NP is not available. Clinicians, however, should take availability, cost, and the presence of liver disease into consideration when deciding which bone turnover marker is most appropriate when evaluating patients with Paget's disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26037791     DOI: 10.1007/s00198-015-3095-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  32 in total

1.  Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.

Authors:  Ian R Reid; James S Davidson; Diana Wattie; Fiona Wu; Jenny Lucas; Gregory D Gamble; Michael D Rutland; Tim Cundy
Journal:  Bone       Date:  2004-07       Impact factor: 4.398

2.  Increased osteoprotegerin in Italian haemodialysis patients.

Authors:  F M Ulivieri; D Marchelli; G Como; G Valente; P Messa; A R Raimondi; L P Piodi
Journal:  Osteoporos Int       Date:  2006-12       Impact factor: 4.507

3.  Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity.

Authors:  F Pons; L Alvarez; P Peris; N Guañabens; S Vidal-Sicart; A Monegal; J Pavía; A M Ballesta; J Muños-Gómez; R Herranz
Journal:  Nucl Med Commun       Date:  1999-06       Impact factor: 1.690

4.  Evaluation of circulating type I procollagen propeptides in patients with Paget's disease of bone.

Authors:  M R Bonnin; C Moragues; J M Nolla; F J Lirón; D Roig-Escofet; M A Navarro
Journal:  Clin Chem Lab Med       Date:  1998-01       Impact factor: 3.694

5.  Characteristics and familial aggregation of Paget's disease of bone in Italy.

Authors:  Daniela Merlotti; Luigi Gennari; Beatrice Galli; Giuseppe Martini; Anna Calabrò; Vincenzo De Paola; Elena Ceccarelli; Paolo Nardi; Annalisa Avanzati; Ranuccio Nuti
Journal:  J Bone Miner Res       Date:  2005-03-28       Impact factor: 6.741

6.  Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.

Authors:  Nancy Laurin; Jacques P Brown; Jean Morissette; Vincent Raymond
Journal:  Am J Hum Genet       Date:  2002-04-30       Impact factor: 11.025

7.  The use of a whole body index with bone scintigraphy to monitor the response to therapy in Paget's disease.

Authors:  K Griffith; D Pearson; C Parker; S Thorpe; R M Vincent; D J Hosking
Journal:  Nucl Med Commun       Date:  2001-10       Impact factor: 1.690

8.  Pain in Paget's disease: a retrospective study of treatment efficacy.

Authors:  Alessandro Zati; Biagio Carmine Colori; Silvia Bonfiglioli Stagni; Annarosa Mignani
Journal:  Neuro Endocrinol Lett       Date:  2011       Impact factor: 0.765

9.  Skeletal distribution and biochemical parameters of Paget's disease.

Authors:  P J Meunier; C Salson; L Mathieu; M C Chapuy; P Delmas; C Alexandre; S Charhon
Journal:  Clin Orthop Relat Res       Date:  1987-04       Impact factor: 4.176

10.  Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.

Authors:  C de la Piedra; A Rapado; E M Díaz Diego; M A Díaz Martín; C Aguirre; E López Gavilanes; M Díaz Curiel
Journal:  Calcif Tissue Int       Date:  1996-08       Impact factor: 4.333

View more
  18 in total

1.  Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.

Authors:  Yair Liel; Muhammad Abu Tailakh
Journal:  Endocrine       Date:  2018-11-08       Impact factor: 3.633

2.  Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.

Authors:  Yair Liel; Muhammad Abu Tailakh
Journal:  Endocrine       Date:  2019-06-04       Impact factor: 3.633

3.  Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.

Authors:  Sang Fu; Yang-Na Ou; Zhi-Feng Sheng
Journal:  Endocrine       Date:  2019-06-01       Impact factor: 3.633

Review 4.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

Review 5.  Paget's Disease of Bone.

Authors:  Luigi Gennari; Domenico Rendina; Alberto Falchetti; Daniela Merlotti
Journal:  Calcif Tissue Int       Date:  2019-01-23       Impact factor: 4.333

6.  Skeletal dissemination in Paget's disease of the spine.

Authors:  Tim Rolvien; Sebastian Butscheidt; Jozef Zustin; Michael Amling
Journal:  Eur Spine J       Date:  2018-01-17       Impact factor: 3.134

7.  Peri-operative derangement in liver function tests in older patients with neck of femur fracture.

Authors:  J Powell; A Michael
Journal:  Osteoporos Int       Date:  2021-01-18       Impact factor: 4.507

Review 8.  Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease.

Authors:  Matthew B Greenblatt; Joy N Tsai; Marc N Wein
Journal:  Clin Chem       Date:  2016-12-09       Impact factor: 8.327

9.  Adult Paget's disease of bone.

Authors:  Stephen P Tuck; Julie Walker
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

10.  Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget's disease.

Authors:  Henry C Tseng; Ching-Chang Ko; Jennifer Martinez; Sing-Wai Wong; Bo-Wen Huang; Xiangxiang Hu; Eui Ho Kim; Joseph P Kolb; Ricardo J Padilla; Peng Xue; Lufei Wang; Thomas H Oguin; Patricia A Miguez
Journal:  Cell Death Differ       Date:  2019-05-10       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.